Overview

A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Women With Endometriosis.

Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the safety and efficacy of 3 asoprisnil doses (0.5 mg, 1.5 mg, and 5.0 mg) for 12 weeks in women with endometriosis.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott
Collaborator:
Jenapharm GmbH & Co. KG